Synthesis of dibenzodioxazocines and their effects on cholinesterases and muscarinic cholinergic receptors.
A new family of tricyclic compounds, the dibenzodioxazocines were synthesized. These compounds were the following: 2-chloro-12-(2-piperidino-ethyl)-dibenzo d,g 1,3,6 dioxazocine hydrochloride: EGYT-2347, 2-chloro-12-(3-dimethylamino-2-methyl-propyl)-dibenzo [d,g] [1,3,6]-dibenzodioxazocine hydrochloride: EGYT-2509, 2-chloro-12-(3-dimethylamino-propyl)-dibenzo [d,g] [1,3,6] dioxazocine-maleate: EGYT-2474 and 2-chloro-12-2-(4-methyl-piperazino)-ethyl-dibenzo [d,g] [1,3,6]-dioxazocine-dihydrochloride: EGYT-2541. These compounds are inhibitors of both butyryl- and acetylcholinesterase to and they exhibited relatively good anticholinergic properties in receptor binding experiments. The most selective inhibitor of butyrylcholinesterase is the compound EGYT-2347 (Ki = 1.5 x 10(-7) M) which strongly binds to rat brain muscarinic cholinergic receptor (KD = 4.1 x 10(-8) M).
Gaál
J
J
Chinoin Pharmaceutical and Chemical Works Co. Ltd., Budapest, Hungary.
Batke
J
J
Borsodi
A
A
Rózsa
L
L
Somogyi
G
G
D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D002417:Cattle; D002800:Cholinesterase Inhibitors; D003989:Dibenzoxazepines / Q000138:chemical synthesis / Q000378:metabolism / Q000494:pharmacology*; D005260:Female; D006168:Guinea Pigs; D007082:Ileum / Q000187:drug effects / Q000378:metabolism; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D051381:Rats; D011976:Receptors, Muscarinic / Q000187:drug effects* / Q000378:metabolism; D013329:Structure-Activity Relationship
D002800:Cholinesterase Inhibitors; D003989:Dibenzoxazepines; D011976:Receptors, Muscarinic; C039088:2-chloro-12-(2-piperidinoethyl)dibenzo(d,g)-1,3,6-dioxazocine; C049176:EGYT 2509